David Rodman sells large blocks of Mineralys common stock

Mineralys Therapeutics reports multiple sales of Common Stock by David Rodman.

Rhea-AI Filing Summary

Mineralys Therapeutics reports multiple sales of Common Stock by David Rodman. The filings list a series of dispositions between 01/02/2026 and 03/12/2026, including transfers of 192,715 shares on 01/05/2026 and smaller tranches through March.

Transactions are characterized as cash or broker‑assisted cashless exercises and list per‑trade share counts and proceeds, indicating routine insider dispositions over the stated period.

Insights

Corporate Governance Analyst

Series of scheduled insider dispositions by a single reporting person over two months.

The record shows repeated sales by David Rodman from 01/02/2026 through 03/12/2026, with a large block of 192,715 shares on 01/05/2026. The entries list gross proceeds per trade, indicating executed dispositions rather than grants.

These appear as routine liquidity events; cashflow recipients are the selling holder(s). Subsequent filings would be required to see aggregated impact on beneficial ownership.

Equity Compensation Specialist

Transactions include both cash and broker‑assisted cashless exercises tied to option exercises.

The excerpt shows exercises dated 03/12/2026 and 03/12/2025 with listed share counts 7,709 and 6,349, respectively, described as "Broker assisted cashless exercise" and "Cash." These labels identify the settlement method for option exercises.

Such mixed settlement methods are common for option liquidity; the filing does not state tax treatment or remaining option positions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions does MLYS disclose in this Form 144?

The Form 144 records multiple dispositions by David Rodman between 01/02/2026 and 03/12/2026. Notable entries include a sale of 192,715 shares on 01/05/2026 and several smaller tranches across January–March.

Were any option exercises reported in the MLYS excerpt?

Yes. The excerpt lists option exercises on 03/12/2026 described as a "Broker assisted cashless exercise" for 7,709 shares and a 03/12/2025 "Cash" exercise for 6,349 shares, showing mixed settlement methods.

How are proceeds shown for the reported transactions in the MLYS filing?

Each trade line includes gross proceeds figures for the selling transactions, for example 6,749,100.06 associated with 192,715 shares on 01/05/2026. The entries list per‑trade proceeds alongside share counts.

Does the Form 144 excerpt show a change in beneficial ownership for MLYS?

The excerpt lists multiple sales by a reporting person but does not state aggregate post‑transaction beneficial ownership totals. It documents per‑trade dispositions and proceeds without summarizing remaining holdings or percentage ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 04:50 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001672659
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Mineralys Therapeutics, Inc.
SEC File Number	001-41614
Address of Issuer	150 N. RADNOR CHESTER RD. SUITE F200 RADNOR PENNSYLVANIA 19087
Phone	(888) 378-6240
Name of Person for Whose Account the Securities are To Be Sold	Rodman David Malcom
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	14058	369225.07	79139956	03/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	03/12/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			7709	03/12/2026	Broker assisted cashless exercise
Common Stock	03/12/2025	Exercise of employee stock options	Mineralys Therapeutics, Inc.			6349	03/12/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/05/2026	192715	6749100.06
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/02/2026	70037	2511919.03
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/09/2026	2170	72195.90
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/12/2026	6348	205142.99
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/13/2026	7709	252469.75
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/14/2026	11367	370645.39
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	01/20/2026	416	13353.60
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/09/2026	2171	65585.91
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/12/2026	6349	184076.52
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/16/2026	14055	385732.29
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/17/2026	417	11505.03
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	03/09/2026	2171	58269.64
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	03/12/2026	6348	173748.15

144: Remarks and Signature

Remarks
Date of Notice	03/13/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	David Rodman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)